Parker B, Ward T, Hayward O, Jacob I, et al. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study. PLoS One 2021;16:e0245955.
PMID: 33529201